New Cancer Vaccine under Investigation by ReGen Factor
New Cancer Vaccine under Investigation by ReGen Factor Table of Contents 1. What is the WT1 Anti-Cancer Peptide 2. Clinical Evidence Related to WT1 3. Approval Status by International Regulatory Bodies 4. WT1 Injection Process 1. What is the WT1 Anti-Cancer Peptide Background 1: Alarming Cancer Incidence Rates in China China has entered a high-incidence […]
Basic Fibroblast Growth Factor
Report to Dr. Jones 15 July 2024 Basic fibroblast growth factor (bFGF) can be applied to the fallopian tubes as a therapeutic agent aimed at promoting tissue repair and regeneration. The application of bFGF involves several potential methods: 1. Direct Instillation: Similar to the G-CSF instillation procedure used in fertility treatments, bFGF can be directly […]
Age Reversal Breakthrough: Harvard/MIT Discovery Could Enable Whole-Body Rejuvenation
Age Reversal Breakthrough Scientists from Harvard Medical School, the University of Maine, and MIT have published a groundbreaking study revealing a chemical method to reprogram cells to a more youthful state. This technique offers a potential alternative to gene therapy for reversing aging. The implications of this research are vast, with potential applications in regenerative […]
Research on (bFGF) in Infertility Treatmen
Report to Dr. Jones Basic Fibroblast Growth Factor (bFGF) in Infertility Treatment: A Comprehensive Review Introduction Infertility affects a significant portion of the global population, with various underlying causes contributing to this condition. Among these, fallopian tube damage or obstruction is a critical factor. Basic fibroblast growth factor (bFGF) has emerged as a promising therapeutic […]
Approved Applications of bFGF
Stephen Blignaut, Brookvale NSW 2100 Australia August 5, 2024 Overview of Basic Fibroblast Growth Factor (bFGF) Basic Fibroblast Growth Factor (bFGF), also known as FGF-2, is a potent growth factor involved in various biological processes such as cell proliferation, differentiation, angiogenesis, and wound healing. Due to its diverse range of functions, bFGF has been utilized […]
ReGen Factor to Seek FDA Approval for Groundbreaking Diabetic Ulcer Treatment Utilizing Bio-Identical Fibroblast Growth Factor (bFGF)
FOR IMMEDIATE RELEASE ReGen Factor to Seek FDA Approval for Groundbreaking Diabetic Ulcer Treatment Utilizing Bio-Identical Fibroblast Growth Factor (bFGF) Australia – August 1, 2024 – ReGen Factor, a leading Australia-based biotechnology company specializing in bio-identical fibroblast growth factors (FGFs), proudly announces its plans to seek FDA approval for its revolutionary treatment targeting diabetic ulcers. […]
ReGen Factor’s Advanced Memory Factor: Harnessing Alpha-GPC and Neurotrophic Factors to Combat Brain Health Issues
FOR IMMEDIATE RELEASE ReGen Factor’s Advanced Memory Factor: Harnessing Alpha-GPC and Neurotrophic Factors to Combat Brain Health Issues Australia – August 1, 2024 – ReGen Factor, renowned for its innovative approach to bio-identical fibroblast growth factors (FGFs), is exploring new frontiers in brain health with its cutting-edge product, Advanced Memory Factor. This novel treatment aims […]
Press Release: ReGen Factor Announces New PET NMN Supplement for Dogs and Cats
Press Release: ReGen Factor Announces New PET NMN Supplement for Dogs and Cats 25 July 2024 Sydney, Australia – ReGen Factor, a leading innovator in the field of regenerative medicine and biotechnology, is thrilled to announce the launch of our groundbreaking PET NMN supplement, specifically formulated for dogs and cats. This advanced supplement is designed […]
NMN and Exosome Research in Veterinary Applications
NMN and Exosome Research in Veterinary Applications 25 June 2024 Sydney, Australia by Claire Ironside Abstract This paper explores the implications of Nicotinamide Mononucleotide (NMN) and exosome therapies in veterinary medicine. Given the increasing demand for advanced pet care solutions, NMN and exosomes offer promising avenues for treating age-related diseases and improving overall pet health. […]
ReGen Factor Shareholder Update – H2 2024
Prioritizing FDA applications for diabetic ulcers and diabetic retinopathy using their recombinant human basic Fibroblast Growth Factor (rh bFGF). This shift addresses substantial unmet medical needs, potentially accelerating regulatory timelines and market entry. Introduction Dear Shareholders, We are delighted to provide you with an update on our strategic initiatives and recent progress as we advance […]
